Resources from the same session
37MO - HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer
Presenter: Yutian Zou
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Webcast
38MO - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Results from TROPION-Breast01 China cohort
Presenter: Shusen Wang
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 37MO and 38MO
Presenter: Hee Kyung Ahn
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session: Breast cancer
Resources:
Webcast
3MO - Efficacy of neoadjuvant pembrolizuamb in early triple-negative breast cancer according to germline BRCA-1/2 mutation
Presenter: Jee Hung Kim
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
28MO - Dynamic evolution of vascular features based on magnetic resonance imaging to predict pathological response and survival outcomes in breast cancer patients undergoing neoadjuvant chemotherapy
Presenter: Qiong Wu
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast